Holen Sie sich die Stockscreener-App
1.305
3.71%
-0.055
Schlusskurs vom Vortag:
$1.36
Offen:
$1.37
24-Stunden-Volumen:
127.99K
Relative Volume:
0.12
Marktkapitalisierung:
$17.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.51M
KGV:
-0.9886
EPS:
-1.32
Netto-Cashflow:
$-8.02M
1W Leistung:
-2.28%
1M Leistung:
+2.30%
6M Leistung:
-3.71%
1J Leistung:
+22.38%
1-Tages-Spanne:
$1.30
$1.38
1-Wochen-Bereich:
$1.2333
$1.38
52-Wochen-Spanne:
$0.58
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Firmenname
Hoth Therapeutics Inc
Sektor
Branche
Telefon
(646)756-2997
Adresse
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Vergleichen Sie HOTH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.3095 | 17.44M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.97 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.72 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.56 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
590.47 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.14 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-10-15 | Eingeleitet | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Aktie (HOTH) Neueste Nachrichten
What drives Hoth Therapeutics Inc. stock priceGame-changing returns - Autocar Professional
Hoth Therapeutics Inc. Stock Analysis and ForecastHigh-yield trading alerts - Autocar Professional
What analysts say about Hoth Therapeutics Inc. stockConsistent triple returns - jammulinksnews.com
Is Hoth Therapeutics Inc. a good long term investmentLightning-fast capital gains - jammulinksnews.com
Hoth Therapeutics shares fall 1.52% intraday after signing VA research deal to advance GDNF as breakthrough therapy for obesity and fatty liver. - AInvest
Hoth Therapeutics partners with VA to test GDNF therapy for obesity By Investing.com - Investing.com South Africa
Hoth Therapeutics partners with VA to test GDNF therapy for obesity - Investing.com Australia
New Weight Loss Drug Challenger GDNF Takes On Semaglutide in Landmark VA Obesity Study - Stock Titan
Why Hoth Therapeutics Inc. stock attracts strong analyst attentionElite Investor Club - Newser
How Hoth Therapeutics Inc. stock performs during market volatilitySwing Trade Signals - Newser
What makes Hoth Therapeutics Inc. stock price move sharplyDaily Volume Leaders - Newser
Hoth Therapeutics (NASDAQ:HOTH) Upgraded by Wall Street Zen to Hold Rating - Defense World
Traumatic Brain Injury Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market | Daily Courier - FinancialContent
Hoth Therapeutics Advances HT-001 for Cancer Treatment - TipRanks
HT-001's Breakthrough in Oncology Supportive Care: A Game-Changer for Hoth Therapeutics? - AInvest
Hoth Therapeutics stock rises after positive Phase 2a trial results By Investing.com - Investing.com UK
Leading Cancer Experts Reveal Phase 2 Data for Revolutionary Skin Toxicity Treatment HT-001 - Stock Titan
Hoth Therapeutics Regains Nasdaq Compliance on June 18 - TipRanks
Hoth Therapeutics reports positive preclinical safety data for HT-KIT By Investing.com - Investing.com South Africa
Hoth Therapeutics Regains Nasdaq Compliance - MarketScreener
Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid - Investing.com
Hoth Therapeutics Just Cleared Critical Nasdaq Hurdle: What This Means for Its $1B+ Biotech Pipeline - Stock Titan
Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT Dose-Dependent Liver Activity with No Observed Toxicity Supports Ind Pathway - MarketScreener
Hoth Therapeutics reports positive preclinical safety data for HT-KIT - Investing.com
Hoth Therapeutics (HOTH) Reports Promising Preclinical Outcomes for Cancer Drug | HOTH Stock News - GuruFocus
Cancer Drug Breakthrough: Hoth's HT-KIT Achieves Perfect Safety Profile Ahead of Clinical Trials - Stock Titan
Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid By Investing.com - Investing.com India
Market Momentum Report: Hoth Therapeutics Inc (HOTH)’s Negative Close at 1.30 - DWinneX
Hoth Therapeutics Joins 20,000 Biotech Leaders at World's Largest Industry Convention - Stock Titan
Hoth Therapeutics (HOTH) Secures Patent for HT-KIT Platform in J - GuruFocus
Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World
Hoth Therapeutics secures Japanese patent for mast cell disease treatment By Investing.com - Investing.com South Africa
Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases - MarketScreener
Hoth Therapeutics secures Japanese patent for mast cell disease treatment - Investing.com
Hoth Therapeutics Secures 15-Year Japanese Patent Protection for Revolutionary Mast Cell Disease Platform - Stock Titan
Hoth Therapeutics (HOTH) Receives 'Buy' Rating from D. Boral Capital | HOTH Stock News - GuruFocus
Hoth Therapeutics plans expanded access program for cancer skin toxicity drug - Investing.com India
Hoth Therapeutics plans expanded access program for cancer skin toxicity drug By Investing.com - Investing.com South Africa
Hoth Therapeutics, Inc. Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities - MarketScreener
Hoth Therapeutics Launches Expanded Access Initiative For HT-001 - MarketScreener
HOTH Seeks Expanded Access for HT-001 to Address Skin Toxicities | HOTH Stock News - GuruFocus
Finanzdaten der Hoth Therapeutics Inc-Aktie (HOTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.34%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):